Therion Biologics

Therion Biologics
Based: Cambridge, MA
Founded: 1991

Why It's Fierce: It's show time for Therion. The FDA has OK'd a pivotal Phase III trial of its lead vaccine candidate, Panvac, an experimental treatment for metastatic pancreatic cancer in patients who have failed treatment with gemcitabine. The trial -- involving 250 patients with advanced pancreatic cancer -- is proceeding under a Special Protocol Assessment, which is likely to speed up assessment of a marketing application. Its primary goal is to improve the survival rate of patients compared with supportive care and chemo.

What to look for: Therion's second vaccine candidate, Prostvac-VF, is currently in Phase II clinical trials for the treatment of prostate cancer.

Therion Biologics

Suggested Articles

With a new research team, outlook and more than a little help from the tech world, GSK has been quietly going about shoring up its pipeline.

The World Health Organization has called out Big Pharma for its dearth of antibiotic innovation amid a growing threat of antimicrobial resistance.

The trial hit its primary endpoint by the time of an interim analysis, enabling Chi-Med to stop the study and start work on a filing for approval.